Nav: Home

New testing method developed for genetic mutation that causes pulmonary hypertension

August 09, 2016

Pulmonology and genetics experts from two Utah healthcare organizations have collaboratively developed a new diagnostic genomic testing method for a rare form of pulmonary hypertension caused by a genetic mutation they discovered three years ago.

The new testing method is a significant improvement for patients because it utilizes a simple blood sample, eliminating the need for a much more invasive lung biopsy that was previously required to test for the genetic mutation.

Pulmonology and genetics experts from Intermountain Medical Center and ARUP Laboratories in Salt Lake City say their new genomic testing method for the gene named EIF2AK4 will result in two major advances: improvement in the accurate diagnosis and proper treatment for patients with the genetic mutation and rare form of pulmonary hypertension and an increase in awareness about the genetic disorder among the public and healthcare providers.

"The new testing methodology is a model of how genomic testing can and will undoubtedly provide better outcomes for many disorders and lower the cost of healthcare delivery and lower risks to patients," said Gregory Elliott, MD, chairman of the department of medicine at Intermountain Medical Center. "It involves a rare disease, but this theme will be repeated again and again in so many ways."

Intermountain and ARUP have entered into a licensing agreement for the new testing method, making it available through ARUP Laboratories.

Dr. Elliott and his colleagues at Intermountain Medical Center collaborated with ARUP molecular genetic scientist Hunter Best, PhD, and his team, to identify the genetic mutation in 2013. The scientists found that mutations in the identified gene EIF2AK4 lead to rare forms of pulmonary hypertension -- known as pulmonary capillary hemangiomatosis (PCH) and pulmonary venoocclusive disease (PVOD).

PCH is defined by uncontrolled growth of the capillaries in the lungs and occurs most commonly in adults aged 20 to 40 years old, but can affect people of all ages. PVOD is defined by the widespread obstruction of the pulmonary veins, which can lead to heart failure.

Not everyone who has the mutation will develop pulmonary hypertension, but the mutation running in the family is a predictor of the disease, which has a high mortality rate: half of all patients with the disease die within two years.

Symptoms for PCH and PVOD are identical to regular pulmonary hypertension, including both its heritable and idiopathic types, which are relatively common. Because of this, the potential impact of the new testing method for patient is significant.

"Traditionally patients who have this condition have to undergo a lung biopsy to confirm the diagnosis," said Dr. Best, who is the medical director of Molecular Genetics at ARUP. "Now, we can simply take a blood sample and confirm the diagnosis through genetic testing."

Dr. Best says identifying causative mutations in the gene EIF2AK4, will eliminate the need for patients to receive a lung biopsy, which can be risky and invasive.

"The discovery will eventually lead to improved care, and believe it or not, lower costs for patients," Dr. Elliott said. "It provides more proof of Intermountain's hypothesis that better care costs less. The biggest savings will come from accurate diagnosis, which will reduce the use of ineffective and potentially harmful interventions."
ARUP Laboratories is a worldwide leader in innovative laboratory research and development. Intermountain Medical Center is the flagship facility for the Intermountain Healthcare system.

Intermountain Medical Center

Related Pulmonary Hypertension Articles:

Evidence review supports pediatric use of PDE-5 inhibitors for pulmonary hypertension
A systematic review of the comparative effectiveness and safety of phosphodiesterase type 5 inhibitors in pediatric patients with pulmonary hypertension published Feb.
Selexipag in pulmonary arterial hypertension: Added benefit not proven
The data in the dossier were unsuitable to show an added benefit: Comparator therapy and division of the population were inadequate.
YEARS algorithm in suspected pulmonary embolism: Towards a reduced rate of pulmonary imaging
Patients with suspected pulmonary embolism often undergo computed tomography pulmonary angiography to confirm or exclude the diagnosis.
New understanding of pulmonary hypertension leads to promising drug targets
A groundbreaking study from the University of Pittsburgh and UPMC identifies new compounds that could have robust effects in treating pulmonary hypertension.
New testing method developed for genetic mutation that causes pulmonary hypertension
Pulmonology and genetics experts from two Utah healthcare organizations have collaboratively developed a new diagnostic genomic testing method for a rare form of pulmonary hypertension caused by a genetic mutation they discovered three years ago.
Early echocardiography to study pulmonary hypertension in mouse model of bronchopulmonary dysplasia
Researchers at Baylor College of Medicine who focus on bronchopulmonary dysplasia and pulmonary hypertension, a common lung disease in premature infants, have shown that echocardiography can be used to detect the pulmonary hypertension in neonatal mice at an earlier time point than previously thought.
Protein target may block deadly arterial remodeling in pulmonary hypertension
Pulmonary hypertension is a highly lethal disease that transforms the thin, flexible vasculature of the lungs into thick, dysfunctional blood vessels that can kill.
Blood test shows promise in gauging severity of pulmonary arterial hypertension
Johns Hopkins Medicine researchers report that rising blood levels of a protein called hematoma derived growth factor are linked to the increasing severity of pulmonary arterial hypertension, a form of damaging high blood pressure in the lungs.
Pulmonary artery stiffening is an early driver of pulmonary hypertension
In this issue of JCI Insight, a team led by Laura Fredenburgh of Brigham and Women's Hospital shows that alterations in pulmonary arterial stiffness occur early during disease and promote vascular remodeling by altering signaling mediated by prostaglandins, a class of hormones that regulate inflammation, smooth muscle contraction, and vasoconstrictoin.
Gene therapy halts pulmonary hypertension progression in large animal pre-clinical study
Scientists have used a novel gene therapy to halt the progression of pulmonary hypertension, a form of high blood pressure in the lung blood vessels that is linked to heart failure.

Related Pulmonary Hypertension Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Digital Manipulation
Technology has reshaped our lives in amazing ways. But at what cost? This hour, TED speakers reveal how what we see, read, believe — even how we vote — can be manipulated by the technology we use. Guests include journalist Carole Cadwalladr, consumer advocate Finn Myrstad, writer and marketing professor Scott Galloway, behavioral designer Nir Eyal, and computer graphics researcher Doug Roble.
Now Playing: Science for the People

#530 Why Aren't We Dead Yet?
We only notice our immune systems when they aren't working properly, or when they're under attack. How does our immune system understand what bits of us are us, and what bits are invading germs and viruses? How different are human immune systems from the immune systems of other creatures? And is the immune system so often the target of sketchy medical advice? Those questions and more, this week in our conversation with author Idan Ben-Barak about his book "Why Aren't We Dead Yet?: The Survivor’s Guide to the Immune System".